TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

SERONO

OncologyNeurologyImmunology
Biotech

SERONO is a biotechnology company focused on Oncology, Neurology, Immunology.

1975
Since
5
Drugs
-
Trials
0
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

No recent activity
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 75%
0 drugs Phase 3: 9 Phase 2: 12 Phase 1: 34
Neurology 13%
1 drugs Phase 3: 2 Phase 2: 1 Phase 1: 1
Immunology 7%
0 drugs Phase 2: 4 Phase 1: 1
Gastroenterology 5%
0 drugs Phase 3: 1 Phase 1: 2

Pipeline Strength Pro

Loading...